ESR1 and prostate carcinoma: Having shown the anti-tumor capability of iTS CM, we next evaluated the efficacy in tumor suppression using 3 freshly isolated human cancer tissues from patients with breast cancer (estrogen receptor-positive and -negative) and prostate cancer.